Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biomedical To Decide On 2005 U.S. Flu Vaccine Production By Late January

This article was originally published in The Pink Sheet Daily

Executive Summary

Vancouver-based company will meet with FDA in January to determine whether it will be able to pursue accelerated licensure for Fluviral. The company has reached guaranteed U.S. purchase and distribution agreements with Henry Schein, AmerisourceBergen and McKesson potentially worth $2.5 bil. over 10 years.
Advertisement

Related Content

Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
GSK To Gain Fluviral Vaccine Through Acquisition Of ID Biomedical
FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway
ID Biomedical To Initiate Fluviral Trial For U.S. Approval By End Of January
New Flu Vaccines May Take Some Of Fluvirin’s Market Share, Chiron Says
CDC, Distributors Could Sue Chiron For Failing To Supply Fluvirin
ID Biomedical Has 1.2 Mil. Extra Doses Of Fluviral For This Season
Chiron Flu Vaccine Reinspection Expected In December

Topics

Advertisement
UsernamePublicRestriction

Register

PS058518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel